

ANTISENSE THERAPEUTICS LIMITED

COMMUNICATIONS POLICY

Communications to Investors & Other Market Participants

The purpose of this policy is to describe the process by which Antisense Therapeutics communicates with its investors and other market participants.

All Antisense Therapeutics directors, employees, consultants and other advisors to Antisense Therapeutics are to comply with the following policy:

- All information released to the Australian Stock Exchange (ASX) (including annual reports, half-yearly reports, and notices of general meetings and their associated explanatory material) will be posted on the Antisense Therapeutics website as soon as practicable following confirmation of receipt by the Australian Stock Exchange.

Annual reports (if requested) and notices of general meetings with explanatory material will also be mailed to investors. The Corporations Act and any other relevant legislation and regulations will be adhered to with respect thereto (also see Antisense Therapeutics' Code of Conduct).

- Under certain circumstances it may be necessary to request a trading halt from the ASX. The managing director will make all decisions relating to trading halts.
- Antisense Therapeutics acknowledges the importance of its relationships with investors and industry analysts and from time to time provides briefings to them. With respect thereto, the following will apply:
 - The managing director and company secretary are to approve all such updates/briefings in advance, including associated materials to be presented.
 - Where the ASX Listing Rules permit Antisense Therapeutics not to disclose material information, such information will not be disclosed at these briefings except where it has been previously disclosed or is simultaneously disclosed to the market.
 - A copy of any material presented at these briefings which is regarded as new will be posted to Antisense Therapeutics' website.
- Antisense Therapeutics may review analysts' research reports and receive questions from investors or analysts relating to its business, but will limit its comments/responses to matters of fact and material previously disclosed by it. No forecast information will be provided unless previously announced to the ASX.

Any questions with respect to this policy should be directed to Antisense Therapeutics' company secretary.